Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth

SONG LIANG1*, RENHUA GUO2*, ZHIHONG ZHANG3*, DONGXIAO LIU4, HAO XU1, ZEKUAN XU1, XUERONG WANG5 and LI YANG1

Departments of 1General Surgery, 2Medical Oncology and 3Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing; 4Department of General Surgery, The Second Affiliated Hospital of South-east University, The Second Hospital of Nanjing, Nanjing; 5Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China

Received January 21, 2013; Accepted March 15, 2013

DOI: 10.3892/or.2013.2397

Abstract. The increase of eukaryotic translation initiation factor 4E (eIF4E) expression is frequently observed in several types of cancer, making eIF4E an attractive anticancer drug target. However, the role of eIF4E in gastric cancer pathogenesis remains unclear. Perifosine is a bioavailable alkylphospholipid exhibiting antitumor activity in a series of cancer types. In this study, gastric cancer cell lines were selected to explore the role of eIF4E as a potential target for treating human gastric cancer. The expression of total eIF4E (T-eIF4E) and phosphorylated eIF4E (p-eIF4E) in gastric cancer samples was detected by immunohistochemical assay. RNA interference was used to silence eIF4E expression. Sulforhodamine B assay was performed to evaluate tumor cell viability. Colony formation assay was used to examine the effects of eIF4E small interfering RNA (siRNA) or perifosine on colony formation. The mRNA levels of eIF4E were analyzed by qRT-PCR and western blot analysis was carried out to evaluate the expression of Akt and eIF4E. The results showed that increased expression levels of T-eIF4E and p-eIF4E were found in gastric cancer tissues and cells. Reduced eIF4E expression blocked the proliferation of gastric cancer cells. Perifosine downregulated the T-eIF4E and p-eIF4E levels in a dose- and time-dependent manner; it also inhibited the growth of gastric cancer cells. Moreover, this inhibitory effect was significantly enhanced by the combination of eIF4E siRNA and perifosine treatments. Our results indicate that eIF4E gene silencing can inhibit tumor cell growth, and eIF4E can be developed as a promising therapeutic target for gastric cancer.

Introduction

Gastric cancer, a leading cause of cancer-related mortality worldwide, is the fourth most frequent malignancy. Despite marked improvements in surgical, chemo-, radio- and other adjuvant therapies, the 5-year survival rate of patients at the advanced stage remains <20-25% (1,2). In recent years, emerging evidence has revealed various genetic changes involved in the progression of gastric cancer. It is critical to investigate the precise molecular mechanism of gastric cancer development for improved anticancer therapeutics.

Eukaryotic translation initiation factor 4E (eIF4E) plays a crucial role in several human tumors, including breast, head and neck, bladder, cervical, lung and prostate cancer (2). Enhanced eIF4E function resulting from eIF4E overexpression or activation of the Ras and phosphatidylinositol 3-kinase/Akt pathways can selectively upregulate the translation initiation of cancer-related mRNA, such as c-Myc, cyclin D1 and Bcl-2 for tumor growth, angiogenesis and cell survival (3-5). The overexpression or knockdown of eIF4E provides insights into its functional significance in tumorigenesis. Knockdown of eIF4E can suppress proliferation and angiogenesis (1,6). Additionally, elevated eIF4E expression confers resistance to multiple chemotherapy agents. A combination of chemotherapy with eIF4E silencing was reported to increase sensitivity to chemotherapeutic drugs such as cryptotanshinone, cisplatin, adriamycin, paclitaxel and docetaxel (4,7,8).

Perifosine is a synthetic alkylphosphocholine (9), exhibiting antitumor activity through blocking cell membrane recruitment of the N-terminal Akt pleckstrin homology (PH)
domain. It also exerts an antitumor effect through MAPK pathway inhibition while inducing c-Jun NH2-terminal kinase (JNK) and upregulating death receptor 5 (DR5) (10-12). The clinical efficacy of perifosine was evaluated in a phase I clinical trial in patients with advanced tumor. Perifosine showed potent anticancer efficacy in a variety of types of cancer, including breast, prostate and renal cell cancer (13-15). However, there has been no report on the effect of perifosine against human gastric cancer cells, and its molecular mechanism has yet to be fully elucidated.

In the present study, we first examined the expression of total eIF4E (T-eIF4E) and phosphorylated eIF4E (p-eIF4E) in human tissues and gastric cancer cell lines, and analyzed the correlation between T-eIF4E and p-eIF4E levels and the clinicopathological characteristics of gastric cancer. We then discussed the proliferation of human gastric cancer SGC7901 and MGC803 cells following eIF4E gene silencing. Furthermore, we investigated the eIF4E signaling pathway regulated by perifosine and the growth inhibitory effect of perifosine on gastric cancer cells. We further identified a combined effect of eIF4E small interfering RNA (siRNA) and perifosine on the growth of gastric cancer cells. These findings identified the oncogenic function of eIF4E and presented the possibility of eIF4E as an effective antitumor target in gastric cancer.

Materials and methods

Reagents. Perifosine was purchased from Selleck Chemicals LLC (Houston, TX, USA) and was dissolved in PBS to make a 50 mmol/l stock solution and stored at -20°C. RPMI-1640 culture medium was purchased from Gibco-BRL (Grand Island, NY, USA). Sulforhodamine B (SRB) was purchased from Sigma Chemical Co. The Lipofectamine 2000 transfection reagent was purchased from Invitrogen Life Technologies (Carlsbad, CA, USA). Rabbit polyclonal antibodies against p-Akt (s473) (9271) and eIF4E (9742), and rabbit monoclonal antibody against Akt (9272) were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). Rabbit monoclonal antibody against actin (sc-130300) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Rabbit polyclonal anti-GAPDH (AP0063) was purchased from Bioworld Technology Inc. (Louis Park, MN, USA). Rabbit monoclonal antibody against p-eIF4E (s209) (2227-1) was purchased from Epitomics Inc. (Burlingame, CA, USA).

Human tissue samples and immunohistochemical assay. The tissues used in this study were obtained from 42 gastric cancer samples and 42 adjacent normal mucosal tissues from patients (32 men and 10 women; age range, 31-77 years) who underwent curative gastrectomy at the First Affiliated Hospital of Nanjing Medical University since 2012. The histologic types and staging of the gastric cancer samples were recorded in accordance with the Lauren and TNM classifications (proposed by the American Joint Committee, 2010 version) respectively. None of the patients had conducted routine treatment including chemotherapy and radiotherapy. Immunohistochemical staining was conducted on serial sections for formalin-fixed and paraffin-embedded tissues. The T-eIF4E and p-eIF4E were detected using a labelled streptavidin biotin (LSAB) method following autoclave antigen retrieval. The slides were then incubated with 3% hydrogen peroxide for 15 min to block endogenous peroxidase activity. Immunohistochemical staining was performed on a BenchMark XT (Ventana Medical Systems, Inc., Tucson, AZ, USA) according to the manufacturer's instructions. Finally the slides were lightly counterstained with hematoxylin. Immunohistochemical staining was assessed according to the immunoreactive score (IRS) that evaluated the staining intensity and the proportion of positive tumor cells. The staining intensity was graded as 0 (no staining), 1 (light yellow), 2 (yellow) and 3 (dark yellow). The proportion of positive tumor cells was scored as 0 (negative), 1 (>10%), 2 (10-50%), and 3 (>50%). The two scores were multiplied and the IRS was determined: values ≥3 were defined as cytoplasmic expression positive, and values <3 were regarded as negative.

Cells and cell culture. The gastric cancer cell lines SGC7901, MGC803, AGS and MKN45 were obtained from the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, China. The cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum (Gibco-BRL; FBS) at 37°C in an incubator containing 95% air and 5% CO2.

RNA interference. The oligonucleotides of siRNA targeting eIF4e (5’-AAGGACGATGGCTAATTACAT-3’) and a non-targeting control were chemically designed and synthesized by Invitrogen Life Technologies. MGC803 and SGC7901 cells were seeded in 6-well plates at a density of 3.6x10^4 cells/well and transfected with 100 nmol/l eIF4e or control siRNAs for 24 h using Lipofectamine 2000 (Invitrogen Life Technologies) according to the manufacturer's instructions. The cells were reseeded to 96-well plates and then treated with perifosine for a further 3 days for SRB assay. The cells transfected with the above siRNAs for 48 h were harvested for total RNA, the purification of whole protein lysates, quantitative real-time PCR (qRT-PCR) assay and western blot analysis.

SRB assay. Gastric cancer cells (3x10^3) were plated in 96-well plates for 24 h and then treated with perifosine (0.125-15 µmol/l). The cells following RNA interference were seeded in 96-well plates (1.5x10^3 cells/well) and treated with different concentrations of perifosine for 72 h. Monolayer cells were fixed and stained with 0.4% (w/v) SRB. Finally, the dye was dissolved in 10 mM Tris base solution for 5 min at room temperature with agitation. Absorbance was measured at 500 nm using a µQuant Universal Microplate Spectrophotometer (BioTek Instruments, Inc.).

Colony formation assay. MGC803 and SGC7901 cells were seeded in 24-well plates for 24 h and then exposed to different concentrations of perifosine (0.25-15 µmol/l). After cultivating in RPMI-1640 medium containing 10% FBS for 12 days, the resulting cell colonies were fixed and stained with 0.5% crystal violet for 10 min. All colonies visible with the naked eye (>50 cells) were counted individually and their colony formation rates were evaluated (clone formation rate = the number of clones/well/100). Each clone was repeated in triplicate.

Two days after siRNA transfection, 100 cells from each of the siRNA, negative control and blank groups were seeded in
24-well plates and cultured in 3 ml RPMI-1640 medium with 10% FBS for 12 days. All colonies visible with the naked eye were counted individually and the clone formation rates were evaluated.

**qRT-PCR.** Total RNA was extracted using TRIzol reagent (Invitrogen Life Technologies) according to the manufacturer’s instructions and treated with RNase-free DNase. Then, cDNA was prepared using M-MLV reverse transcriptase (Promega, Madison, WI, USA). qRT-PCR analysis was performed using a Power SYBR-Green PCR Master Mix from Applied Biosystems, Inc. (Foster City, CA, USA) under the following conditions: 10 min at 95˚C followed by 40 cycles at 95˚C for 15 sec, 60˚C for 1 min using the ABI PRISM 7300 sequence detection system of Applied Biosystems Inc. The relative expression levels of target genes were calculated through normalizing to the expression of the control gene GAPDH in each experiment.

The sequences of specific primers were: eIF4E, 5'-CCT ACAGAACAGATGGGCACTC-3' (forward) and 5'-GCC CAAAAGTCTTCAACAGATCA-3' (reverse); GAPDH, 5'-ATGGGGAAGGTGAAGGTCG-3' (forward) and 5'-GGG GTCATGTAGGCAACATA-3' (reverse) and were designed and synthesized by Invitrogen Life Technologies, Inc.

**Western blot analysis.** RIPA lysis buffer was purchased from Cell Signaling Technology, Inc. and was stored at 4˚C. Protease inhibitors were added prior to use. Cells were harvested after treatment and subjected to western blot analysis as previously described (16).

**Statistical analysis.** All data from three independent experiments are expressed as the means ± SD. Differences between the groups were assessed by two-sided unpaired Student’s t-test. The Fisher’s exact test or the χ² test was used to test the correlation between eIF4E expression and clinicopathological parameters. P<0.05 was considered to indicate a statistically significant difference. The IC₅₀ value of perifosine was calculated by Bliss software.

**Results**

**Expression of T-eIF4E and p-eIF4E correlates with the clinicopathological parameters of gastric cancer.** Due to the frequently elevated level of eIF4E in the progression of human cancer (17), we examined the expression of T-eIF4E and p-eIF4E in gastric cancer samples (Fig. 1). T-eIF4E and p-eIF4E were overexpressed in gastric tumor tissues compared with adjacent non-cancerous tissues. The positive rate of T-eIF4E and p-eIF4E was 78.57% (33/42) and 76.19% (32/42), respectively. T-eIF4E and p-eIF4E were mainly seen in the cytoplasm of primary cancer cells. Table I shows the correlation between T-eIF4E and p-eIF4E expression and clinicopathological parameters in gastric cancer. A significant correlation was found between T-eIF4E overexpression and distance metastasis in patients (P=0.026) (Table I), which was consistent with previous studies (2). The results indicated eIF4E gene expression may be involved in the development and could be used as an independent prognosis marker in patients with gastric cancer.

**Expression of eIF4E is higher in gastric cancer cells than in human gastric epithelial cells.** To further investigate the relationship between elevated eIF4E levels and gastric cancer, we examined the mRNA and protein levels of eIF4E in gastric cancer SGC7901 and MGC803 cells, as well as human gastric epithelial cells (GES-1) using qRT-PCR assay and western blot analysis. The expression of eIF4E mRNA was higher in gastric cancer cells than in GES-1 cells (Fig. 2A). Western blot analysis showed that T-eIF4E and p-eIF4E expression levels were considerably higher in gastric cancer cells than in GES-1 (Fig. 2B). These results indicated that eIF4E functions as an oncogene in gastric cancer.

**Downregulation of eIF4E expression reduces the growth of gastric cancer cells.** To investigate the potential functions of eIF4E gene in gastric cancer, we first explored the effect of eIF4E silencing on the growth of MGC803 and SGC7901 cells.
Table I. The correlation between T-eIF4E and p-eIF4E expression and the clinicopathological characteristics in gastric cancer patients.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total</th>
<th>-</th>
<th>+</th>
<th>P-value</th>
<th>-</th>
<th>+</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60</td>
<td>20</td>
<td>4</td>
<td>16</td>
<td>1.000</td>
<td>4</td>
<td>16</td>
<td>0.849</td>
</tr>
<tr>
<td>≥60</td>
<td>22</td>
<td>5</td>
<td>17</td>
<td>0.753</td>
<td>6</td>
<td>16</td>
<td>0.454</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>32</td>
<td>6</td>
<td>26</td>
<td>0.823</td>
<td>6</td>
<td>9</td>
<td>0.145</td>
</tr>
<tr>
<td>Female</td>
<td>10</td>
<td>3</td>
<td>7</td>
<td>1.000</td>
<td>2</td>
<td>3</td>
<td>0.418</td>
</tr>
<tr>
<td>Tumor size</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤5 cm</td>
<td>27</td>
<td>6</td>
<td>21</td>
<td>1.000</td>
<td>8</td>
<td>19</td>
<td>0.418</td>
</tr>
<tr>
<td>&gt;5 cm</td>
<td>15</td>
<td>3</td>
<td>12</td>
<td></td>
<td>2</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>TNM stage&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I, II</td>
<td>15</td>
<td>4</td>
<td>11</td>
<td>0.823</td>
<td>6</td>
<td>9</td>
<td>0.145</td>
</tr>
<tr>
<td>III, IV</td>
<td>27</td>
<td>5</td>
<td>22</td>
<td></td>
<td>4</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>Depth of invasion (T)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1, T2</td>
<td>15</td>
<td>4</td>
<td>11</td>
<td>0.823</td>
<td>6</td>
<td>9</td>
<td>0.145</td>
</tr>
<tr>
<td>T3, T4</td>
<td>27</td>
<td>5</td>
<td>22</td>
<td></td>
<td>4</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis (N)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>15</td>
<td>4</td>
<td>11</td>
<td>0.823</td>
<td>5</td>
<td>10</td>
<td>0.483</td>
</tr>
<tr>
<td>N1-3</td>
<td>27</td>
<td>5</td>
<td>22</td>
<td></td>
<td>5</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Distant metastasis (M)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>4</td>
<td>3</td>
<td>1</td>
<td>0.026</td>
<td>1</td>
<td>3</td>
<td>1.000</td>
</tr>
<tr>
<td>No</td>
<td>38</td>
<td>6</td>
<td>32</td>
<td></td>
<td>9</td>
<td>29</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>Patient stage was determined according to the UICC TNM classification. eIF4E, eukaryotic translation initiation factor 4E; T-eIF4E, total eIF4E; p-eIF4E, phosphorylated eIF4E.

In the qRT-PCR assay, a significantly decreased level of eIF4E mRNA was observed after 48 h transfection of 100 nmol/l eIF4E siRNA in comparison with a control siRNA in MGC803 and SGC7901 cells (Fig. 3A). Western blot analysis confirmed a significantly decreased level of T-eIF4E and p-eIF4E (s209), indicating a successful eIF4E knockdown (Fig. 3B). Our results showed that the gastric cancer cells with eIF4E siRNA exhibited markedly higher growth inhibition rates compared with the cells with a control siRNA (P<0.01) in a 5-day SRB assay (Fig. 3C and D), which was consistent with previous reports on breast cancer, primary central nervous system lymphoma cells (18,19). Moreover, such inhibitory effects were also seen when the cells were transfected with eIF4E siRNA in a 10-day colony formation assay (Fig. 3E and F) and its colony formation rate was significantly lower in comparison with the control group. The result indicated that downregulation of eIF4E expression reduced the possibility of colony formation.

Perifosine decreases eIF4E mRNA level and inhibits the Akt/eIF4E signaling pathway while downregulating T-eIF4E and p-eIF4E protein expression. Due to the crucial role of eIF4E in the growth of gastric cancer, we further examined the levels of eIF4E following perifosine (an Akt inhibitor) treatment. We explored whether perifosine reduced the proliferation
of gastric cancer cells through regulating the Akt signaling pathway. After 24 h of treatment, perifosine significantly downregulated the level of eIF4E mRNA in SGC7901 cells (P<0.05), but showed a mild change and not in a time- and dose-dependent manner (Fig. 4A and B); perifosine (0.25, 0.5, 0.75 and 1.0 µmol/l) produced the dose-dependently decreased expression of T-eIF4E and p-eIF4E in SGC7901 cells (Fig. 4D and E). In MGC803 cells, the expression of eIF4E mRNA was significantly downregulated by perifosine in a dose-dependent manner (Fig. 4C). Furthermore, we also examined the expression of total Akt and p-Akt (s473), and the T-eIF4E and p-eIF4E (s209) were also decreased in a dose- and time-dependent manner in MGC803 cells (Fig. 4F and G). These results indicated that eIF4E could be a target of perifosine in gastric cancer, and the Akt/eIF4E signaling pathway was involved in the regulation mechanism of perifosine.

Perifosine inhibits the growth of gastric cancer cells in a dose-dependent manner. Perifosine dose-dependently decreased the viability of gastric cancer cells at the concentrations ranging from 0.625 to 15 µmol/l in a 3-day SRB assay (Fig. 5A). Among these cell lines, SGC7901 was the most sensitive to perifosine treatment with an IC50 of 0.36 µmol/l. The IC50 of MGC803, MKN45 and AGS cells was 5.18, 11.65 and 4.0 µmol/l respectively, which indicated that perifosine inhibited the growth of gastric cancer cells with different sensitivity. In addition, peri-
fosine dose-dependently substantially decreased the ability of MGC803 (Fig. 5B) and SGC7901 (Fig. 5C) cells to form colonies in a dose-dependent manner.

**Co-targeting eIF4E enhances the inhibitory effect on gastric cancer SGC7901 and MGC803 cells.** Since perifosine inhibited the growth of gastric cancer cells, we used RNA interference to block eIF4E expression and then evaluated the combined effect of eIF4E siRNA and perifosine on gastric cancer cell lines. The results of qRT-PCR assay showed eIF4E siRNA had a very high inhibitory effect on eIF4E in SGC7901 and MGC803 cells (Fig. 3A). Western blotting also confirmed the knockdown rate of eIF4E (Fig. 3B). The combined treatment of eIF4E siRNA and perifosine enhanced the inhibitory effect on gastric cancer cell growth (Fig. 6A and B). We further examined the eIF4E signaling pathway regulated by perifo-
After SGC7901 and MGC803 cells transfected with eIF4E siRNA or a control siRNA were treated with perifosine, eIF4E expression was further downregulated (Fig. 6C and D). The results suggested the combination of eIF4E siRNA and perifosine may represent an effective therapy against gastric cancer.

**Discussion**

Abnormal eIF4E activity is present in a large spectrum of human malignancies. eIF4E overexpression has been commonly seen in the prostate, breast, stomach, colon, lung, skin and hematopoietic system. p-eIF4E has oncogenic potential in human cancer (20,21). However, little is known about the relationship between the eIF4E gene and gastric cancer progression. In the current study, we found that the expression levels of T-eIF4E and p-eIF4E were upregulated in gastric cancer samples. Further analysis showed that T-eIF4E expression was related to cancer vascular invasion, suggesting T-eIF4E promoted the progression of gastric cancer. However, we did not find a relationship between p-eIF4E expression and any clinical characteristics of the patients. Meanwhile, due to limited samples, the relationship between T-eIF4E and p-eIF4E expression and the malignancy of human tumors remains to be further determined. These data indicate that the eIF4E gene may be an attractive target for gastric cancer therapy.
Translation activation is critical for cancer cell growth and survival. Therefore, translation is a rational target for novel cancer therapeutics. Translation initiation is largely dependent on eIF4E activity. According to research on different types of tumors, eIF4E can be regulated by the PI3K/mTOR, MAPK/MNK signaling pathways at multiple levels, such as transcription, serine 209 phosphorylation, as well as the inhibitory interaction between binding proteins (4EBP) (22,23). Furthermore, the difference between eIF4E activation and response to eIF4E siRNA suggests varying influence of the Akt pathway depending on cell types. In this study, we found that eIF4E was overexpressed in gastric cell lines and knockdown of eIF4E in MGC803 and SGC7901 cells through RNA interference significantly inhibited in vitro proliferation. Therefore, eIF4E may play an important role in gastric cancer, and clarification of the eIF4E signaling pathway is urgently required.

Perifosine, an alkylphospholipid with antitumor activity in both preclinical and clinical studies, inhibits Akt through targeting its pleckstrin homology (PH) domain and interferes with its recruitment to the plasma membrane and subsequent phosphorylation and activation (24). In the present study, we investigated the effect of perifosine on human gastric cancer SGC7901, MGC803, AGS and MKN45 cells. Our results indicate that perifosine treatment has a significant cytotoxic effect on SGC7901, MGC803, AGS and MKN45 cells in a dose-dependent manner, which is associated with rapidly decreased Akt activation as assessed by the quantification of Ser473 phosphorylation and the decreased T-eIF4E and p-eIF4E expression. Previous studies have indicated that eIF4E is one of the proposed downstream mediators in the Akt signaling pathway and regulated by Akt. These findings indicate that perifosine may downregulate the expression of eIF4E through Akt inhibition (25).

We first observed that perifosine downregulated T-eIF4E and p-eIF4E expression and inhibited the Akt/eIF4E signaling pathway in gastric cancer. We also noted less changed eIF4E amounts at the mRNA level in SGC7901 cells than at the protein level, which suggested the involvement of other mechanisms in addition to transcriptional regulation. Furthermore, enhanced eIF4E level has been demonstrated to increase the expression of proteins that contribute to tumor development, including growth factors such as c-Myc and cyclin D1, and angiogenesis factors such as VEGF and FGF-2. Perifosine inhibited the proliferation of gastric cancer cells through decreasing eIF4E levels. Further studies on whether the inhibition of eIF4E by perifosine also inhibits the expression of other downstream targets that are necessary for oncogenesis and cancer progression are warranted.

After identifying that the eIF4E signaling pathway was regulated by perifosine, we also found that the combination of eIF4E gene silencing and perifosine treatment could significantly increase the growth inhibition efficacy in human gastric cancer cells in comparison with eIF4E gene silencing or perifosine treatment alone. Cancer cells tend to be more highly dependent on translation than normal tissues. Targeting eIF4E appears to be an attractive anticancer strategy for chronic myeloid leukemia and endometrial adenocarcinoma (5,7,18). Increasing evidence supports that inhibited eIF4E can cause more inhibitory effects on drug-induced growth (8). Therefore, suppressing translation by targeting eIF4E with RNA interference may play a more important role in perifosine-induced growth repression. The result may suggest a possible strategy of combined eIF4E knockdown.

In conclusion, the current results showed that the expression of T-eIF4E and p-eIF4E was increased in gastric cancer tissues and cell lines. Downregulation of eIF4E significantly suppressed the proliferation of gastric cancer cells. Moreover, perifosine exerted its inhibitory effect on the regulation of growth and survival through the eIF4E signaling pathway and the combination of eIF4E gene silencing and perifosine was more effective than eIF4E gene silencing or perifosine alone. Further research might focus on a specific mechanism through which eIF4E regulates the growth of gastric cancer and may confirm the potential effectiveness of eIF4E as a therapeutic target of gastric cancer in clinical practice.

Acknowledgements

This study was supported by the Jiangsu Province’s Key Provincial Talents Program, China (RC2011059) (L.Y.), and the ‘Six Talents Peak’ Project of Jiangsu Province (2012) (L.Y.), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and the National Natural Science Foundation of China (nos. 30873099, 81102458 and 81172004) (X.W.). The authors also thank Professor Xuerong Wang of Nanjing Medical University for the valuable comments on this study.

References


